Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



Theranexus announces the publication of a scientific article on the mechanism of action of drug candidate THN102 in the international journal of neuropsychopharmacology
22/05/2018
Download PDF file (262 Ko)

Theranexus publishes its cash position as at 31st March 2018
15/05/2018
Download PDF file (204 Ko)

Theranexus presentation at the International Connexins Symposium(Vancouver 14-15 May 2018)
07/05/2018
Download PDF file (273 Ko)

Oral presentation of Theranexus at the 9th European congress on narcolepsy 5 and 6 may in Montpellier
02/05/2018
Download PDF File (279 Ko)

Theranexus announces its 2017 annual results and presents an update on the progress of its clinical trials
26/04/2018
Download PDF File (427 Ko)

21 juin 2018 : Kepler Biotech Days, Paris

10 juillet 2018: Solebury Trout Summer EU Investor Tour, Paris

8 & 9 octobre 2018 : Large & MidCap Event, Paris

4 & 5 décembre 2018 : European MidCap Event, Genève

22 janvier 2019: Conférence Biomed, Paris